about us main logo
pipeline
technology
investorinfo

nnvcinthenews

NanoViricides Inc.

1 Controls Drive,
Shelton, CT 06484
Ph No:- 203-937-6137
Fax No:- 203-859-5095
Email:- info@nanoviricides.com

 

 

 

 

 

 

 

 



 

 


marker     Press Releases - All

 

 

  • July 11, 2024 - A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

  • July 1, 2024 - NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections

  • June 24, 2024 - A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

  • June 20, 2024 - A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

  • June 11, 2024 - NV-387 has recently completed Phase I human clinical safety tolerability studies with no reported adverse events in India, as the Company has reported previously

  • June 4, 2024 - This is NHP PK profile of NV-387 which showed desirable unusually slow decline

  • May 29, 2024 - A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More - Novel Host-Mimetic, Virus Killing Technology Platform

  • May 23, 2024 - NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc

  • May 20, 2024 - The RSV animal study lung histopathology results are astounding. They indicate complete cure ofRSV by NV-387 treatment. Only partial protection for some time by ribavirin treatment.

  • May 15, 2024 - NanoViricides Has Filed its Quarterly Report - NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection

  • May 14, 2024 - A Novel Broad-Spectrum Antiviral with Activity Against RSV – Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment

  • May 10, 2024 - NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

  • May 8, 2024 - A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox – NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides

  • May 6, 2024 - NA Novel Broad-Spectrum Antiviral with Activity Against Influenza A – NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides

  • April 30, 2024 - NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

  • February 15, 2024 - NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

  • February 1, 2024 - Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

  • January 29, 2024 - Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

  • January 4, 2024 - NanoViricides to Present at the Biotech Showcase in San Fransisco

    •  

  • November 28, 2023 - The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

  • November 15, 2023 - NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

  • November 14, 2023 - Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

  • October 16, 2023 - NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV

  • October 11, 2023 - NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET

  • August 21, 2023 - The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides

  • July 11, 2023 - Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model

  • July 6, 2023 - Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

  • May 31, 2023 - NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

  • May 16, 2023 - NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin

  • April 25, 2023 - NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient

  • April 17, 2023 - NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate

  • April 5, 2023 - NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates

  • February 15, 2023 - NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials

  • January 4, 2023 - NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT

  • December 6, 2022 - NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 2:00pm ET

  • November 15, 2022 - NanoViricides, Inc. Has Filed its Quarterly Report- Coronavirus Drug NV-CoV-2 IND Stage

  • October 14, 2022 - NanoViricides, Inc. Has Filed its Annual Report- Coronavirus Drug NV-CoV-2 IND Stage

  • August 9, 2022 - NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy

  • August 4, 2022 - NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

  • May 17, 2022 - NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application

  • May 16, 2022 - NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis

  • April 15, 2022 - NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program

  • February 15, 2022 - NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready

  • November 16, 2021 - NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials

  • November 15, 2021 - NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2

  • October 13, 2021 - NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage

  • October 11, 2021 - NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity

  • October 4, 2021 - NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference

  • September 27, 2021 - NanoViricides, Inc. Invites You to Join Us at the Benzinga Healthcare Small Cap Conference for Update on Pan-Coronavirus COVID-19 Drug Development Program

  • September 22, 2021 - Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug

  • September 14, 2021 - NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID- 19 Drug Development

  • May 17, 2021 - NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND

  • March 9, 2021 - NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application

  • March 2, 2021 - NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application

  • February 17, 2021 - NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND

  • February 8, 2021 - NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies

  • January 27, 2021 - Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.'s President, Dr. Anil Diwan

  • November 19, 2020 - NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA

  • November 17, 2020 - NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress

  • November 11, 2020 - NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19

  • October 15, 2020 - NanoViricides, Inc. Has Filed its Annual Report: Strengthened Financial Position and Rapidly Developing Novel Coronavirus Drug Program

  • September 16, 2020 - NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

  • September 2, 2020 - NanoViricides to Present COVID-19 Drug Update at The LD 500 Virtual Conference

  • July 13, 2020 - NANOVIRICIDES CLOSES ON $11.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

  • July 8, 2020 - Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides' SARS-CoV-2 Therapeutics Program

  • June 30, 2020 - NanoViricides Announces Addition to Russell Microcap(R) Index

  • June 23, 2020 - NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2020 - Has Sufficient Cash, Progress on New Coronavirus Drug Program and the Lead HerpeCide™ Drug Candidate IND Application

  • June 9, 2020 - NanoViricides Signs Memorandum of Understanding for Human Coronavirus Drug Development License

  • May 26, 2020 - NanoViricides Announces Completion of $10.2 Million Registered Direct Offering - Funds to Accelerate COVID-19 Drug Program and HerpeCide™ Program

  • May 21, 2020 - NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering

  • May 20, 2020 - Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus

  • May 18, 2020 - Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc

  • May 12, 2020 - NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses

  • May 4, 2020 - NanoViricides Signs Confidential Disclosure Agreement with International Pharmaceutical Company to Explore Collaborating on its COVID-19 Program

  • April 29, 2020 - NanoViricides Presentation on COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 is Now Available

  • April 13, 2020 - NanoViricides' President Dr. Anil Diwan was Interviewed by Proactive Investors About the Company's Antiviral Drug Development Against SARS-CoV-2 to Treat COVID-19

  • April 6, 2020 - U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus Drug Development Efforts

  • March 16, 2020 - Coronavirus Drug Development Update from NanoViricides, Inc.

  • February 24, 2020 - NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2019 - Has Sufficient Cash, HerpeCide™ Drug Candidate IND Application Development in Progress

  • February 12, 2020 - Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc.

  • February 10, 2020 - NANOVIRICIDES PRESIDENT Dr. DIWAN WAS INTERVIEWED BY THE VARNEY SHOW ON FOX BUSINESS NEWS

  • February 4, 2020 - Nanoviricides President Dr. Diwan Was Interviewed By The Kennedy Show On Fox Business News

  • January 30, 2020 - NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus

  • January 24, 2020 - NANOVIRICIDES CLOSES ON $8.625 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

  • January 21, 2020 - NANOVIRICIDES PRICES $7.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

  • January 9, 2020 - NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101

  • January 7, 2020 - NanoViricides Has Initiated Genetic Toxicology Testing Required for an IND for Its Drug Candidate

  • January 6, 2020 - NanoViricides Receives Cash Infusion of $2.25 Million

  • December 9, 2019 - NanoViricides President Dr. Anil Diwan Provides Responses to Shareholder Questions at the Annual Meeting of Shareholders

  • December 6, 2019 - NanoViricides Annual Meeting of Shareholders to be Held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT

  • December 3, 2019 - NanoViricides Founder Dr. Diwan Provides $2,000,000 Loan Commitment to the Company

  • December 2, 2019 - NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND

  • November 18, 2019 - NanoViricides Files Quarterly Report for Period Ending September 30, 2019 - HerpeCide™ Drug Candidate IND Enabling Studies Update, Progressing Towards Clinical Trials

  • November 4, 2019 - NanoViricides Completes Licensing for VZV Field which Includes Shingles Drug Development

  • October 31, 2019 - NanoViricides Initiates Required Dermal Sensitization and Ocular Irritation Testing of Lead Drug Candidate towards IND

  • October 9, 2019 - NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101

  • October 3, 2019 - NanoViricides is Creating Nanomedicines to Develop Antiviral Therapies to Combat Shingles and Herpes Viruses

  • September 30, 2019 - NanoViricides, Inc. Files Form S-1 Registration Statement

  • September 12, 2019 - NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split

  • August 26, 2019 - NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND

  • August 5, 2019 - NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials

  • June 10, 2019 - NanoViricides, Inc. Appoints Dr. Mark Day to its Board of Directors

  • June 3, 2019 - NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate

  • May 20, 2019 - NanoViricides Files Quarterly Report for Period Ending March 31, 2019 - HerpeCide™ Drug Candidate Pre-IND Application Submitted, Progressing Towards Clinical Trials

  • May 13, 2019 - NanoViricides Announces Completion of Production of its Lead Candidate for Upcoming GLP Tox Package Studies

  • April 16, 2019 - NanoViricides Submits Pre-IND Briefing Documents to the US FDA

  • April 9, 2019 - NanoViricides Provides Update on Pre-IND Meeting with the US FDA, GLP Safety/Toxicology Studies to Begin Soon, Multiple Kg Scale Drug Production Accomplished at Its Own Facility

  • March 26, 2019 - NanoViricides has Requested a Pre-IND Meeting with the US FDA

  • March 12, 2019 - NanoViricides Reports Successful Completion of Another Important Safety Study towards an IND

  • March 5, 2019 - NanoViricides Reports Excellent Safety Profile of Its First Drug Candidate in Dermal Treatment Study

  • February 27, 2019 - NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering

  • February 26, 2019 - NanoViricides Reaches an Agreement on Terms of License for Shingles Virus Drug Development

  • February 19, 2019 - NanoViricides Files Quarterly Report for Period Ending December 31, 2018 - HerpeCide Drug Candidate Progressing in IND-Enabling Studies Towards Clinical Trials

  • February 11, 2019 - NanoViricides President Dr. Diwan to Present at the BIO CEO & Investor 2019 Event in New York City Tomorrow Feb 12th at 2-30pm

  • February 4, 2019 - NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials

  • January 7, 2019 - NANOVIRICIDES, INC. CEO DR. TARAPOREWALA TO PRESENT AT THE BIOTECH SHOWCASETM INVESTMENT CONFERENCE IN SAN FRANCISCO ON JANUARY 7, 2019


  • November 26, 2018 - NanoViricides Files Quarterly Report for Period Ending September 30, 2018

  • October 29, 2018 - NanoViricides, Inc. Appoints Mr. James Sapirstein to its Board of Directors

  • October 22, 2018 - NanoViricides CEO Dr. Irach Taraporewala Presents a Letter to Shareholders

  • October 15, 2018 - NanoViricides Has Filed its Annual Report, Company Reports Strong Progress in Advancement of HerpeCide Program

  • September 28, 2018 - NanoViricides Inc. to Present at the MicroCap Conference in New York City on October 1

  • September 5, 2018 - Nanoviricides Inc. to Present at 20th Annual Rodman & Renshaw Conference in NYC on Sept 6th

  • August 7, 2018 - Nanoviricides Reports Its Topical Dermal Shingles Candidates Effective in Reducing Pain in Animal Study

  • July 23, 2018 - NanoViricides Inc. Welcomes Dr. Irach Taraporewala as the New CEO

  • July 12, 2018 - NanoViricides Provides Update on Recent Events

  • June 26, 2018 - Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research

  • May 22, 2018 - NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates

  • May 14, 2018 - NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials

  • April 9, 2018 - NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today


  • December 6, 2017 - Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

  • November 6, 2017 - NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology

  • October 26, 2017 - Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center

  • October 17, 2017 - NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology

  • September 29, 2017 - NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials

  • September 11, 2017 - NANOVIRICIDES, INC. ANNOUNCES ITS CEO Dr. SEYMOUR TO PRESENT AT THE 19TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY ON SEPTEMBER 12, 2017

  • July 10, 2017 - NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin

  • June 26, 2017 - NanoViricides' Poster Novel Nanoviricides Highly Effective Against Varicella Zoster Virus in Cell Culture to be Presented Today at the 2017 Annual Meeting of American Society of Virology

  • June 20, 2017 - NanoViricides' Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology

  • June 13, 2017 - NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City

  • June 6, 2017 - NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies

  • May 16, 2017 - NanoViricides Files Quarterly Report for Period Ending 2017-03-31

  • April 26, 2017 - NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles

  • February 16, 2017 - NanoViricides Files Quarterly Report for Period Ending 2016-12-31

  • February 13, 2017 - NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company


  • December 1, 2016 - NanoViricides Publishes a Letter from the CEO to Shareholders on its Website

  • November 15, 2016 - NanoViricides Files Quarterly Report for Period Ending 2016-09-30

  • November 7, 2016 - NanoViricides President Dr. Diwan Gave Invited Talks on Regulatory Aspects of Nanomedicines

  • October 31, 2016 - NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles

  • October 11, 2016 - NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials

  • August 25, 2016 - NanoViricides Reports on Senator Murphy's Visit to the Company's Shelton Campus

  • June 20, 2016 - NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruses

  • June 9, 2016 - NanoViricides to Present at the LDMicro Invitational Conference

  • June 7, 2016 - NanoViricides to Present at the BIO2016 International Convention - on June 8, 2016, at 11a.m. Pacific Time

  • May 31, 2016 - NanoViricides Signs Agreement with St. Jude Children's Research Hospital for further Influenza Drug Development

  • May 11, 2016 - NanoViricides Files Quarterly Report for Period Ending 2016-03-31

  • March 21, 2016 - NanoViricides, Inc. CEO Dr. Seymour Interview by Small Cap Nation is on YouTube

  • February 22, 2016 - NanoViricides' Anti-Virus Technology Published in Handbook of Clinical Nanomedicine

  • February 16, 2016 - NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the Baylor College of Medicine

  • February 11, 2016 - NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the University of Pittsburgh

  • February 10, 2016 - NanoViricides Files Quarterly Report for Period Ending 2015-12-31

  • February 8, 2016 - NanoViricides CEO to Present at the 18th Annual BIOCEO & Investor Conference on February 8, 2016 and at the Disruptive Growth and Healthcare Conference on February 11, 2016, both in New York City

  • February 1, 2016 - NanoViricides Signs Agreement with the University of Wisconsin for Testing of Anti-Viral Candidates

  • January 25, 2016 - NanoViricides 2015 Annual Shareholders Meeting Was Held on January 23, 2016 - Company Discussed Accomplishments and Future Strategy

  • January 12, 2016 - NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday


  • November 10, 2015 - NanoViricides Files Quarterly Report for Period Ending 2015-09-30

  • September 16, 2015 - NanoViricides Files Annual Report

  • August 17, 2015 - NanoViricides Accelerates its Herpes Drug Development Program

  • August 10, 2015 - NanoViricides Reports that the Dramatic Effects of Its Topical Anti-Herpes Treatment were Reproduced Once Again in an Animal Model in a Different Laboratory

  • May 18, 2015 - NanoViricides Files Quarterly Report for Period Ending 2015-03-31

  • April 27, 2015 - NanoViricides Discusses the Strong Effectiveness of Its Anti-Herpes Drug Candidates in a Lethal Animal Model of Dermal Herpes Infection

  • April 20, 2015 - NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model

  • April 6, 2015 - NanoViricides Provides an Update on Its Progress over the Last Quarter

  • March 9, 2015 - NanoViricides Issued Registered Shares as Interest to Certain Debenture Holders

  • February 25, 2015 - NanoViricides Files Quarterly Report for Period Ending 2014-12-31

  • February 17, 2015 - NanoViricides Announces that a Research Report on the Company has been Published By Midtown Partners, Inc., a New York Investment Bank

  • January 22, 2015 - Nanoviricides Reports that the FluCide® Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study in Rats Performed by BASi

  • January 21, 2015 - NanoViricides, Inc.'s Executive Officers Report Insider Purchases of Common Stock

  • January 7, 2015 - NanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility


  • November 20, 2014 - NanoViricides Says Injectable FluCide™ Selected In Top Ten Project to Watch - Presentation Today At the Therapeutics Area Partnerships Meeting in Boston

  • November 18, 2014 - NanoViricides CEO, Eugene Seymour, MD, MPH, Invited to Discuss the Current Ebola Outbreak on Fox Business News at 9PM EDT Tonight

  • November 17, 2014 - NanoViricides, Inc. Files Quarterly Report - Reports Further Improved Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates

  • October 27, 2014 - NanoViricides, Inc. Signs CRADA for Material Transfer with USAMRIID for Evaluating Its Anti-Ebola Drug Candidates

  • October 7, 2014 - NanoViricides CEO, Eugene Seymour, MD, MPH, Invited to Discuss the Current Ebola Outbreak on Fox Business News at 9PM EDT Tonight

  • October 1, 2014 - NanoViricides Reports FluCide™ Samples Were Shipped To BASi For Start of Safety/Toxicology Studies; Also Reports That Ebola Drug Candidates are Being Synthesized

  • September 30, 2014 - NanoViricides Files Annual Report

  • September 16, 2014 - NanoViricides Reports That Its CEO Dr. Seymour Will Be Interviewed about the Evolving Ebola Crisis on Fox Business News at 9PM EDT This Evening

  • September 9, 2014 - NanoViricides Reports That It Has Designed and Commenced Synthesis of Novel Ebola Drug Candidates; Dr. Seymour To Present At The Rodman And Renshaw Conference In New York Today

  • September 8, 2014 - NanoViricides Raises Approximately $7.5 Million Upon Exercise of Certain Old Warrants by Its Long Standing Investors

  • August 12, 2014 - NanoViricides to Ring Opening Bell at New York Stock Exchange

  • August 4, 2014 - NanoViricides to Restart its Anti-Ebola Virus Drug Development Program

  • July 23, 2014 - NanoViricides President Dr. Diwan was an Invited Participant at the Prestigious CEO Roundtable

  • July 22, 2014 - NanoViricides Inc. Celebrated the Grand Opening of Its New R&D and cGMP Pilot Manufacturing Facility with Congressman Jim Himes as the Chief Guest Yesterday

  • July 14, 2014 - NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference held by GTC Bio on Friday, July 11

  • July 2nd, 2014 - NanoViricides Reports that its Director Dr. Milton Boniuk, a Director, Has Invested $5M into the Company in a Convertible Debenture

  • June 25th, 2014 - NanoViricides Reports that a Certificate of Occupancy has been Issued for the New cGMP Manufacturing and R&D Facility in Shelton, CT

  • June 19th, 2014 - NanoViricides President Dr. Diwan to Present at the Wall Street Analyst Forum Today, June 19th, in New York City

  • June 16th, 2014 - NanoViricides, Inc. Reports That NNVC is in the Preliminary Additions List of The Russell Global, The Russell 3000, The Russell 2000 and the Russell Microcap Indexes

  • June 4th, 2014 - NanoViricides CEO Dr. Seymour to Present at the LD Micro Invitational Conference Today, June 4th

  • May 19th, 2014 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates

  • May 5th, 2014 - NanoViricides Reports Novel Drug Candidates for Treatment of the MERS (Middle East Respiratory Syndrome) Corona Virus Ready For Animal Testing

  • April 16th, 2014 - NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector

  • March 31st, 2014 - NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as Researcher of the Year by BusinessNewHaven, a Connecticut Area Business Journal

  • March 24th, 2014 - NanoViricides Announces Patent Awards in Australia

  • March 12th, 2014 - NanoViricides, Inc. Has Posted Dr. Seymour's CEO Letter on the Company Website - Dr. Seymour to Present today at the Roth Capital Conference

  • March 7th, 2014 - NanoViricides Inc. Denies Rumor That It Is Being Acquired For $4.5B

  • March 5th, 2014 - NanoViricides, Inc. Announces It Has Commenced Action Against Seeking Alpha to Obtain Identity of the Anonymous Short Seller

  • February 26th, 2014 - NanoViricides, Inc. Reports its President & Chairman Dr. Diwan Purchased its Common Stock in the Open Market

  • February 20th, 2014 - NanoViricides Reports that it is Evaluating Purchase of the New Facility and cGMP Pilot Production Plant instead of a Lease

  • February 18th, 2014 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates

  • February 14th, 2014 - NanoViricides, Inc. Demands Retraction of the Baseless and Inaccurate Libelous Article by an Anonymous Short Seller Posted on SeekingAlpha Website

  • February 11th, 2014 - NanoViricides CEO Dr. Seymour to be Interviewed on Radio by Yorba Media at 2PM Eastern

  • February 11th, 2014 - NanoViricides, Inc. Responds to Baseless Seeking Alpha Article

  • February 4th, 2014 - NanoViricides Signs Agreement with Viroclinics Biosciences BV for Testing of Various NanoViricides Against Specific Viruses of Current Concern

  • January 27th, 2014 - NanoViricides Reports Construction of its New Facility and cGMP Pilot Production Plant is Nearing Completion, also Provides Details of its $20 Million Registered Direct Offering

  • January 21st, 2014 - NanoViricides Announces that It Has Raised $20 Million in a Registered Direct Offering


  • December 11th, 2013 - NanoViricides Announces that its Annual Meeting was held on December 9th, 2013; the CEO Presentation is available on the Redesigned Website

  • December 2nd, 2013 - NanoViricides, Inc. Reports Excellent Safety Profile of Its Broad-Spectrum anti-Influenza Drug Candidate, FluCide™ , in a Non-GLP Study

  • November 21st, 2013 - Dengue Fever Case in New York Highlights Importance of NanoViricides DengueCide® Development Program

  • November 18th, 2013 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Clinical Trials of its First Drug Candidate

  • November 11th, 2013 - NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the European Medicines Agency (EMA)

  • November 4th, 2013 - NanoViricides Announces Renewal of DengueCide™ Evaluation Contract with the Professor Eva Harris Laboratory at the University of California, Berkeley

  • October 21st, 2013 - Nanoviricides says early results indicate that FluCide® was extremely safe in a non-GLP small animal tox study

  • October 7th, 2013 - Nanoviricides Announces Initiation of Toxicology Study of FluCide®.

  • October 2nd, 2013 - Nanoviricides, Inc Announces That Its CEO, Eugene Seymour, MD, MPH will Present at LD MICRO Invitational on October 2nd in West Los Angeles

  • October 1st, 2013 - NanoViricides Files Annual Report - Reports Having Sufficient Funds to Advance A Drug Candidate into Clinical Trials

  • September 25th, 2013 - NanoViricides Begins Trading on NYSE MKT National Exchange; CEO Dr Seymour Invited to Speak at Duke University's Fuqua Business School

  • September 23rd, 2013 - NanoViricides to List Common Stock on New York Stock Exchange MKT; Company Stock Symbol Will Remain NNVC

  • September 17th, 2013 - NanoViricides Reports that its Director, Milton Boniuk, MD, has invested a Total of $7M in the Company this year

  • September 16th, 2013 - NanoViricides Reports It Has Successfully Improved HIVCide Drug Candidate in Cell Culture Studies

  • September 12th, 2013 - NanoViricides Announces that It Has Raised approximately $10.33 Million in the Registered Direct Offering Announced Recently and Discusses Shareholder Issues since the Reverse Split

  • September 10th, 2013 - NanoViricides Announces That It Now Meets Listing Standards of Major National Stock Exchanges Upon Executing a Reverse Split of Its Stock; Also Reports It Has Raised Approximately $9.9 Million in a Registered Direct Offering

  • September 3rd, 2013 - NanoViricides Reports that the DengueCide™ Orphan Drug Application Has Been Submitted and Received by the European Medicines Agency

  • August 19th, 2013 - NanoViricides Reports on Construction Progress of its New Facility and cGMP Pilot Production Plant

  • August 7th, 2013 - NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the US FDA

  • August 5th, 2013 - NanoViricides Signs a Non-Disclosure Agreement with the Lovelace Respiratory Research Institute for IND-enabling Efficacy Studies on FluCide® and for Testing its Novel Drug Candidates against the Highly Lethal MERS Human Coronavirus

  • July 22nd, 2013 - NanoViricides Receives Notification that Clinical Coordinators Have Been Appointed by The European Medicine Agency to Review the Company's Upcoming DengueCide Orphan Drug Designation Application

  • July 19th, 2013 - NanoViricides Reports That its CEO was Interviewed on the RedChip Money Report Program on Fox Business News TV Channel Yesterday Evening

  • July 8th, 2013 - NanoViricides Signs Agreement with Public Health England for Testing of Various NanoViricides Against Specific Viruses of Current Concern

  • July 1st, 2013 - NanoViricides Submits DengueCide™ Orphan Drug Designation Letter of Intent to File with the European Medicines Agency

  • June 27th, 2013 - NanoViricides to Present at the OneMedForum-NY 2013 in New York today

  • June 24th, 2013 - NanoViricides Appoints Chancellor of Penn State University, Professor Mukund S Kulkarni as an Independent Board Member

  • June 10th, 2013 - NanoViricides Submits DengueCide™ Orphan Drug Designation Application to the US FDA for dengue and dengue hemorrhagic fever

  • May 28th, 2013 - NanoViricides Appoints Baylor Professor Dr. Milton Boniuk as an Independent Board Member

  • May 21st, 2013 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Initial Clinical Trials of its First Drug Candidate

  • May 13th, 2013 - NanoViricides, Inc. Brings in Experienced Executive as Interim CFO

  • April 24th, 2013 - NanoViricides to Present at the 2013 BIO International Convention in Chicago today

  • April 22nd, 2013 - NanoViricides Anticipates FluCide™ Drug Candidates to be Effective Against H7N9

  • March 20th, 2013 - NanoViricides President Dr. Diwan Invited to Present a Seminar at the Center for Biological Physics and the California NanoSystems Institute at UCLA

  • March 5th, 2013 - NanoViricides to Lead Sessions at the Symposium on Nanomedicines- Roadmap to Commercialization in Rockville, MD tomorrow

  • February 27th, 2013 - NanoViricides announces Retirement of its Series C Convertible Preferred Stock Held by Seaside 88, LP - Company reports having more than two years of cash on hand

  • February 25th, 2013 - NanoViricides, Inc. Announces that Renovation for its cGMP Clinical Drug Facility has Begun; also Addresses Shareholder Concern - Knows No Reason for the Price Drop Yesterday

  • February 19th, 2013 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Phase I Clinical Trials of its First Drug Candidate

  • February 11th, 2013 - NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC tomorrow

  • February 4th, 2013 - NanoViricides Raises $6M from Equity Investors - Reports Having Sufficient Funds for the Initial Human Clinical Trials of its Broad-spectrum anti-Influenza Drug

  • January 15th, 2013 - NanoViricides Update: FluCide Drug Candidates Significantly Superior to Tamiflu in Animal Studies Against H3N2 and H1N1 viruses - Company announces that cGMP Facility Project has Entered Detailed Design Phase

  • January 14th, 2013 - NanoViricides, Inc. Retains AES Clean Technology, Inc. for Design, Engineering and Construction of the Cleanroom Suite in its previously announced cGMP Production and Laboratory Facility

  • January 2nd, 2013 - NanoViricides, Inc. Appoints Id3A, LLC as Architect for its previously announced cGMP Production and Laboratory Facility


  • December 24th, 2012 - NanoViricides announces Completion of Previously Reported $5 Million in Shelf Offering - Company reports having more than two years of cash on hand

  • December 10th, 2012 - NanoViricides Appoints Project Manager and Engineering Firm for FDA cGMP Plant; Provides Update on anti-Influenza Program

  • November 20th, 2012 - NanoViricides Files Quarterly Report - Reports Having Sufficient Funds and Satisfactory Progress in its Advancing Pipeline

  • November 13th, 2012 - NanoViricides Signs Agreement with BASi for Toxicology and Safety Studies

  • October 16th, 2012 - NanoViricides Files Annual Report - Reports Having Sufficient Funds for Current Goals and For Advancing Its Robust Drug Pipeline

  • October 9th, 2012 - NanoViricides Oral FluCide™ Drug Candidate Dramatically Reduced Virus Load and Lung Damage Pathology in the Lungs of Animals Given Lethal H3N2 Influenza Virus Infection, and was Significantly Superior to Oseltamivir

  • September 10th, 2012 - NanoViricides Reports Its Oral FluCide® Anti-Influenza Drug Candidates Are Superior to Oral Oseltamivir (TamiFlu®) in H1N1 Influenza Lethal Infection Model

  • September 4th, 2012 - NanoViricides Reports that Oral Administration of FluCide® Anti-Influenza Drug Candidates Led to Strong Antiviral Antibody Response in a Highly Lethal Animal Model

  • August 27th, 2012 - NanoViricides Reports that Oral Administration of FluCide® Anti-Influenza Drug Candidates Caused Lung Viral Load Decrease Comparable to IV Administration and Far Superior to Oseltamivir, in a Highly Lethal Animal Model

  • August 20th, 2012 - NanoViricides Reports that Oral Administration of FluCide® Anti-Influenza Drug Candidates Led to Survival Improvements Comparable to IV Administration and was Far Superior to Oseltamivir, in a Highly Lethal Animal Model

  • August 13th, 2012 - NanoViricides Reports That Oral Administration of FluCide®, its Anti-Influenza Drug Candidate Was Effective In Animal Model

  • June 29th, 2012 - NanoViricides Raises $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand

  • June 25th, 2012 - NanoViricides Appoints an Independent Board Director and Chairman of the Audit Committee

  • May 21st, 2012 - NanoViricides Files Quarterly Report

  • May 14th, 2012 - NanoViricides Appoints Mr. Andrew Hahn as Consultant for Design and Construction of Pilot cGMP Production Facility

  • May 7th, 2012 - NanoViricides Announces Issuance of a Fundamental Patent in the USA

  • May 1st, 2012 - NanoViricides to Present at the 21st Annual NYBA Meeting in NYC on May 2nd

  • April 2nd, 2012 - NanoViricides Announces Successful Pre-IND Meeting with the US FDA

  • March 5th, 2012 - NanoViricides Announces US FDA Has Confirmed Pre-IND Meeting Date

  • February 13th, 2012 - NanoViricides to Present at the 14th Annual BIO-CEO Conference in NYC today


  • December 5th, 2011 - NanoViricides, Inc Announces That It Has Submitted a Pre-IND Meeting Request to the US FDA For Its Anti-Influenza Clinical Drug Candidate, FluCide™

  • November 15th, 2011 - NanoViricides Files Quarterly Report

  • November 3rd, 2011 - NanoViricides Raises an Additional $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand

  • October 24th, 2011 - NanoViricides' Anti-Virus Technology Published in Bionanotechnology II: Global Prospects

  • October 17th, 2011 - NanoViricides Files Annual Report - Reports Having Sufficient Funds for Current Goals

  • October 4th, 2011 - NanoViricides Inc to Present at the Partnership Opportunities in Drug Delivery (PODD) Conference in Boston Today

  • September 26th, 2011 - NanoViricides Inc to Present at the 10th Annual NanoBusiness Conference

  • September 21st, 2011 - NanoViricides Inc. to Present at the French Biotech Tour - Infectious Diseases Meeting

  • September 19th, 2011 - NanoViricides Announces Acquisition of New Space for Future Pilot cGMP Production

  • September 6th, 2011 - NanoViricides Selects Its First FluCide™ Clinical Candidate For FDA Submission

  • June 16th, 2011 - NanoViricides Announces That Its CEO Will Present Information about the Company at an Investor Meeting June 16th in Denver

  • August 15th, 2011 - NanoViricides Reports Sustained Anti-HIV Effect with Much Shorter Drug Dosing than HAART Drug Cocktail

  • June 6th, 2011 - NanoViricides to Present Influenza Study Results at the TechConnect World 2011 Conference in Boston

  • August 8th, 2011 - NanoViricides Reports That It is Financially Sound and is Progressing Towards Initial FDA Submission

  • May 23rd, 2011 - NanoViricides Files Quarterly Report

  • August 1st, 2011 - NanoViricides Expands On Prior HIVCide Effectiveness Release

  • May 2nd, 2011 - Treatment with NanoViricides FluCide™ Drug Candidates Resulted in a 1000-fold Reduction of Viral Load in the Lungs of Animals Infected with Lethal Dose of Influenza Virus

  • July 27th, 2011 - NanoViricides Raises $2.5M in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand

  • April 20th, 2011 - NanoViricides Raises an Additional $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand

  • July 25th, 2011 - NanoViricides Reports Anti-HIV Efficacy Equivalent to HAART Drug Cocktail Treatment in Animal Study, Successfully Advancing its HIVCide Lead Optimization Program

  • April 7th, 2011 - NanoViricides Reports FluCide™ Drug Candidates Found to Offer Significant Reduction in Damaging White Blood Cell Presence in Lung Tissue in Lethal Influenza Infection Animal Study

  • July 5th, 2011 - NanoViricides Signs Consulting Agreement with BCG for FDA Submission

  • April 4th, 2011 - NanoViricides Reports FluCide™ Drug Candidates Found to Offer Significant Protection Against Devastating Lung Lesions in Lethal Influenza Infection Animal Study

  • June 22nd, 2011 - NanoViricides, Inc., to Present at OneMedForum NY 2011 Trans-Atlantic Conference for Emerging Healthcare and Life Science Companies

  • March 21st, 2011 - NanoViricides Reports Treatment with its FluCide Drug Candidate Achieves Dramatic Full Survival in Recent H1N1 Influenza Lethality Study

  • June 20th, 2011 - NanoViricides to Lease New Space for cGMP Production

  • February 23rd, 2011 - NanoViricides Files Quarterly Report

    • Tab content

     


    Contact Information

    NanoViricides, Inc.
    1 Controls Drive,
    Shelton, CT 06484

    Phone: +1-203-937-6137
    Phone: +1-888-591-3579
    Fax: +1-203-859-5095
    E-mail: info@nanoviricides.com